For year’s investors have wondered where the next Amgen blockbuster would come from.
Today, we have the answer. Amgen received European approval for its new osteoporosis drug Prolia (denosumab). Approval comes across all EU countries, plus Norway, Iceland and the ever-populous Liechtenstein. GlaxoSmithKline (GSK) will co-market Prolia.
The FDA will be taking up Prolia’s fate in July.
